Table 1.
Participants’ demographics and mean score of psychological variables (N = 206 pairs).
| Variables | Mean ± SD (range) | n (%) |
|---|---|---|
| Caregiver characteristics | ||
| Age (years) | 57.61 ± 13.73 (22–86) | |
| Gender | ||
| Male | 77 (37.38) | |
| Female | 129 (62.62) | |
| Marital status | ||
| Single | 8 (3.88) | |
| Married | 197 (95.63) | |
| Divorced | 1 (0.49) | |
| Education | ||
| Primary school and below | 46 (22.33) | |
| Intermediate | 63 (30.58) | |
| High or vocational school | 44 (21.35) | |
| College and above | 53 (25.73) | |
| Religious belief | ||
| Yes | 12 (5.83) | |
| No | 194 (94.17) | |
| Average monthly household income (RMB) | ||
| ≤ 1000 | 30 (14.56) | |
| 1001–3000 | 64 (31.07) | |
| 3001–5000 | 45 (21.84) | |
| ≥ 5000 | 67 (32.52) | |
| Domicile | ||
| Countryside | 82 (39.81) | |
| Town | 124 (60.19) | |
| Relationship with care recipient | ||
| Spouse | 146 (70.87) | |
| Parents | 5 (2.43) | |
| Offspring | 48 (23.30) | |
| Others | 7 (3.40) | |
| Employment status | ||
| Nonworking | 135 (65.53) | |
| On-the-job | 71 (34.47) | |
| Self-health status | ||
| Poor | 4 (1.94) | |
| General | 94 (45.63) | |
| Good | 108 (52.43) | |
| Care duration | ||
| 3–8 h/d | 28 (13.59) | |
| 8–13 h/d | 38 (18.45) | |
| > 13 h/d | 140 (67.96) | |
| Degree of disease understanding | ||
| Ignorant | 49 (23.79) | |
| Partial | 116 (56.31) | |
| Full | 41 (19.90) | |
| Chronic disease | ||
| Yes | 72 (34.95) | |
| No | 134 (65.05) | |
| Score of FCR | 12.05 ± 5.09 (2–34) | |
| Score of caregiver burden | 33.01 ± 10.34 (6–56) | |
| Score of quality of life | 48.04 ± 5.73 (24–64) | |
| Score of resilience | 23.06 ± 5.07 (10–39) | |
| Score of anxiety | 4.56 ± 3.09 (0–21) | |
| Care recipient characteristics | ||
| Age (years) | 63.46 ± 12.50 (18–89) | |
| Gender | ||
| Male | 117 (56.80) | |
| Female | 89 (43.20) | |
| Primary disease | ||
| Lymphoma | 140 (67.96) | |
| Multiple myeloma | 41 (19.90) | |
| Leukemia | 23 (11.17) | |
| Myelodysplastic syndrome | 2 (0.97) | |
| Chemotherapy protocol | ||
| R-CHOP/CHOP | 84 (40.78) | |
| R-CDOP/CDOP | 19 (9.22) | |
| VRD | 25 (12.14) | |
| Azacitidine/Azacitidine with venetoclax | 6 (2.91) | |
| IA/DA | 11 (5.34) | |
| Others | 61 (29.61) | |
| Chemotherapy frequency | ||
| 1–3 times | 108 (52.43) | |
| 4–6 times | 48 (23.30) | |
| > 6 times | 50 (24.27) | |
CDOP, cyclophosphami, liposome doxorubicin, oncovin, prednisone; CHOP, cyclophosphamide, hydroxydaunomycin, oncovin, prednisone; DA, daunorubicin, azacitidine; FCR, fear of cancer recurrence; IA, idarubicin, azacitidine; R-CHOP, rituximab, cyclophosphamide, hydroxydaunomycin, oncovin, prednisone; R-CDOP, rituximab, cyclophosphami, liposome doxorubicin, oncovin, prednisone; SD, standard deviation; VRD, bortezomib, revlimid, dexamethasone.